bluuebunny/crossref_metadata_2025_split huggingface dataset:
Causes and Consequences of Iranian Elite Athletes’ International Migrations
Authors: Salimi Mehdi , Khodaparast Mahboubeh , Nikou Parvaneh Savari 
Published: November 2023

Abstract
This study aimed to identify the causes and consequences of international migrations of Iranian elite athletes. This research was conducted using the qualitative method and Glaser grounded theory approach. The statistical population included senior managers in the Ministry of Sports and Youth and national sports federations, expert researchers in this field, professional athletes who have emigrated or were on the verge of emigration, and coaches in professional sports teams in Iran. Twenty-six people were selected through theoretical sampling and snowball methods. The data collection tool was a semi-structured individual interview. The Glaser approach was used to analyse the data, including two main stages of actual and theoretical coding. During the actual coding process, 468 primary statistical codes were identified, and 68 subcategories and 11 main categories were subsequently identified. The categories were divided into three general dimensions: “Factors affecting”, “Consequences”, and “Strategies” concerning “elite athletes’ emigration “; in the theoretical coding stage, the final model of the research was outlined. Identifying the causes and consequences of the emigration of elite athletes can significantly help the authorities to recognise problems in this area and provide appropriate solutions to retain adequate human capital in the country. We attempted to examine and present the causes and consequences of the emigration of Iranian elite athletes in the form of a model.
The Influence of Tilt on Berkovich Indentation of a Steel Sample Using FEM Analysis and Nanoindentation
Authors: Kovář Jaroslav , Fuis Vladimír , Čtvrtlík Radim , Tomáštík Jan 
Published: November 2023

AbstractThe main shape deviations of a Berkovich indenter are the indenter bluntness and indenter tilt. The influence of the Berkovich indenter tilt on the results of the FEM modelling of steel nanoindentation is evaluated in this paper. The indenter tilt has an impact on the indentation curves and contact area. The X5CrNiCuNb 16-4 steel nanoindentation was modelled by FEM and the indentation curves were obtained. The Berkovich indenter was blunted and the tilt of the indenter was changed to determine its influence on the indentation curves. The results showed that growing tilt shifts the indentation curves to higher values of indentation forces and makes unloading curves steeper which is in agreement with a larger contact area. The calculated indentation curves were compared with the experimental indentation curves and the impact of the indenter tilt to the indentation curves was determined.
Clinical features and outcomes in patients with human immunodeficiency virus-negative, Castleman’s disease: a single medical center study in Tunisia
Authors: Chabchoub Imen , Salah Raida Ben , Kallel Rim , Snoussi Mouna , Frikha Feten , Marzouk Sameh , Boudawara Tahya Sellami , Bahloul Zouhir 
Published: November 2023

Abstract

Introduction:
Castleman’s disease (CD), known as angiofollicular lymph node hyperplasia, is an uncommon condition. The two most common histological subtypes are hyaline vascular and plasma cell. We performed a retrospective analysis to define the clinic-pathological features and survival of CD, which is quite rare focusing on the particularities of our series with a review of the recent literature.

Methods:
This is a retrospective study conducted in the department of internal medicine of Hedi Chaker hospital in Sfax, Tunisia over 25 years. The disease was histologically confirmed in all patients. For each file, we collected a set of data by filling in a pre-designed form.

Results:
18 patients were included. There were 8 men and 10 women with a mean age of 42.8 years. CD was monocentric in 5 cases (28%) and multicentric in 13 cases (72%). Clinically, peripheral adenopathy was present in 77.7% of patients and deep adenopathy in 72.2%. Systemic signs were found in 13 patients, including general condition (4.4%), fever (16.6%), serositis (27.7%), and skin involvement (33.3%).
A biological inflammatory syndrome accompanied the clinical picture in 66% of patients. Abnormalities in the blood count were found in 12 cases (66%), with anemia in 11 cases, thrombocytosis in 3 cases, and hypereosinophilia in 3 cases.
Cutaneous Kaposi’s sarcoma was associated with Castleman’s disease in 2 cases, Hodgkin’s lymphoma, angioimmunoblastic T-cell lymphoma, and lymph node T-cell lymphoma were found in 1 case respectively. 3 of the patients had associated connective tissue diseases such as Sjögren’s syndrome in 2 cases and rheumatoid arthritis in 1 case. HHV8 serology was positive in 1 case with a multicentric plasma cell form.
Histologically, the plasma cell form represented 50% of cases, hyaline-vascular (39% of cases), and mixed (11% of cases).
Therapeutically, high-dose corticosteroid therapy was initiated in 13 cases. As a second-line treatment, MOPP chemotherapy was used in 1 case due to transformation into Hodgkin’s lymphoma, and biotherapy (rituximab) was used in 2 cases in the multicentric form. Surgical removal of superficial adenopathy was performed in 2 patients with monocentric CD.

Conclusion
: Castleman’s disease (CD) is a non-malignant lymphoproliferation of localized or multicentric form with a wide and heterogeneous clinical spectrum. Diagnosis can be difficult due to the lack of clinical and radiological specificity. Management depends on the clinical form involving surgical and/or medical management.
Mohs Appropriate Use Criteria Scores and Treatment of Keratinocyte Carcinoma: Review of 11,145 Tumors
Authors: Hope Richard H. , Dowdle Travis S. , Hope Landon , Pruneda Corley 
Published: November 2023

Background: Various methods are available for treatment of keratinocyte carcinomas (KCs). The Mohs appropriate use criteria (AUC) score was developed to quantify the appropriateness of Mohs micrographic surgery (MMS) based on multiple tumor and patient characteristics.
Objectives: Stratify KCs by treatment modality used and compare to Mohs AUC score.
Methods: Conducted a retrospective review of 11,145 consecutive KCs between 01/2017 and 12/2021, comparing associated Mohs AUC score with modality selected.
Results: The average Mohs AUC score for all KCs combined was 7.1 with 8714 (78.2%) qualifying for MMS via AUC score. However, MMS was only done on 2813 (32.3%) of KCs. Excisional surgery was used to treat 4580 (41.1%) of KCs, 2777 (24.9%) were treated with electrodesiccation and curettage (ED&C), and 732 (6.6%) were treated with biopsy only. Of those KCs treated with excision, ED&C, or a biopsy, 70.7%, 70.7%, and 72.4% reached an “appropriate” Mohs AUC score for MMS respectively.
Limitations: This is a single private practice, with two board certified dermatologists
Conclusions: Mohs AUC score can help determine if a KC warrants MMS; however, in our practice, MMS was necessary for only 32.3% of the KCs that qualified based on the Mohs AUC score.
Efficacy of Secukinumab in Patients With Mild to Moderate Psoriasis: A Pooled Analysis of 6 Phase 3 Studies
Authors: Strober Bruce , Van de Kerkhof Peter , Fan Heng , Levi Eugenia , Blauvelt Andrew 
Published: November 2023

Introduction: Secukinumab has demonstrated sustained long-term efficacy for the treatment of patients with moderate to severe plaque psoriasis, but efficacy in mild to moderate psoriasis has not been rigorously evaluated. The secukinumab phase 3 clinical trial program included patients with mild to moderate psoriasis among populations with active psoriatic arthritis (EXCEED and FUTURE 2-5; NCT02745080, NCT01752634, NCT01989468, NCT02294227, and NCT02404350), and among patients with moderate to severe palmoplantar psoriasis (GESTURE; NCT01806597). Here, we report efficacy and safety of secukinumab in a pooled population of patients with mild to moderate psoriasis.
Methods: This post hoc analysis included patients from the phase 3 EXCEED, FUTURE 2-5, and GESTURE trials, with mild to moderate psoriasis defined as either a baseline affected body surface area (BSA) of 3%-10% or a baseline Investigator’s Global Assessment modified 2011 score (IGA) of 2 or 3. Patients were pooled by treatment received through Week 16 (treatment period 1) and from Weeks 16 to 52 (treatment period 2), according to the following groups: treatment period 1 (secukinumab 300 mg, secukinumab 150 mg, or placebo) and treatment period 2 (secukinumab 300 mg or secukinumab 150 mg). Efficacy was assessed by the proportion of patients achieving 75% improvement in the Psoriasis Area and Severity Index (PASI75), PASI90, and PASI100 among patients with a BSA 3%-10%; and by IGA 0/1 response with ≥2-point improvement among patients with baseline IGA score of 2 or 3. Descriptive statistics were reported for each outcome. Missing data were imputed using non-responder imputation.
Results: Overall, 654 patients and 971 patients had mild to moderate psoriasis at baseline as defined by a BSA of 3%-10% or IGA score of 2 or 3, respectively. Demographics and baseline disease characteristics were similar between populations defined by BSA and by IGA. Among patients with a baseline BSA of 3%-10%, secukinumab resulted in greater achievement of PASI75/90/100 vs placebo at Week 12 (secukinumab 300 mg: 62.8%/44.4%/33.1%; secukinumab 150 mg: 48.0%/29.1%/19.4%; placebo: 11.7%/9.0%/8.0%), with increased responses at Week 52 (secukinumab 300 mg: 65.7%/56.5%/47.3%; secukinumab 150 mg: 58.1%/40.5%/31.3%). The proportion of patients with baseline IGA=2 or 3 achieving IGA 0/1 response with ≥2-point improvement was greater among patients receiving secukinumab 300 mg (46.6%) or 150 mg (37.2%) than placebo (8.6%) at Week 12, with increased responses at Week 52 (secukinumab 300 mg: 52.5%; secukinumab 150 mg: 44.4%).
Conclusions: Secukinumab led to improvements in measures of disease severity among patients with mild to moderate psoriasis after 12 weeks of treatment vs placebo in a pooled analysis of patients with psoriatic arthritis or palmoplantar psoriasis. Both doses of secukinumab showed increased efficacy from Week 12 to Week 52.
Time to Onset of a Minimal Clinically Important Difference in DLQI with Guselkumab Treatment in VOYAGE 1
Authors: Abbarin Nastaran , Papp Kim , Langley Richard , Adam David , Ho Vincent , Park-Wyllie Laura , Miller Megan , You Yin , Yang Ya-Wen , Gooderham Melinda 
Published: November 2023

Introduction Psoriasis (PsO) is a chronic inflammatory disease of the skin. While skin clearance, as measured by the Psoriasis Area and Severity Index (PASI), is a clinical goal, PsO patients also suffer from reduced health-related quality of life (HRQoL). In the Phase 3 VOYAGE 1 trial, guselkumab (GUS) demonstrated improvements on patient reported outcomes compared with placebo (PBO) and adalimumab (ADA). Here we report an analysis of the estimated time to onset of the minimal clinically important difference (MCID) in HRQoL, as measured by the Dermatology Quality of Life Index (DLQI) and associated PASI response in GUS-treated patients from VOYAGE 1.
Methods The VOYAGE 1 trial enrolled patients with moderate-to-severe PsO who were randomized to receive PBO, GUS, or ADA. The DLQI is a self-report measure for HRQoL ranging from 0 (no impact) to 30 (maximum impact) that assesses the effect of skin problems on 6 HRQoL domains. An accepted MCID in DLQI is 4, previously reported as the smallest difference in DLQI total score that patients’ rate as beneficial. DLQI score and PASI improvement (percent change from baseline) were analyzed at Weeks 0, 8, 16, and 24 for the subset of VOYAGE 1 patients with a baseline DLQI score >4. Earliest time to onset of MCID in mean DLQI and corresponding mean PASI improvement were estimated using linear interpolation for the GUS group between Weeks 0 and 8.
Results Among patients randomized to GUS, n=279 (85%) had DLQI >4 at baseline. By first assessment at Week 8 (W8), we observed a reduction in the mean DLQI score from 15.6 (baseline) to 5.0 (W8) with median DLQI decreasing from 15.0 (baseline) to 3.0 (W8). The interpolated onset of MCID in DLQI occurred at 21.1 days (W3) following the initial GUS dose. In GUS-treated patients, the estimated mean PASI improvement corresponding to the onset of MCID in mean DLQI occurring at Week 3 was 29.2%.
Conclusions These data indicate that the onset of clinically meaningful improvements in mean DLQI occur as early as after the first dose of GUS in patients with moderate-to-severe PsO.
A Phase 3b Study Evaluating Safety and Efficacy of Risankizumab in Adult Patients with Moderate-to-Severe Plaque Psoriasis with Palmoplantar (Non-Pustular) Involvement
Authors: Lebwohl Mark , Bukhalo Michael , Gold Linda Stein , Pelle Michelle , Glick Bradley , Llamas-Velasco Mar , Sanchez-Rivera Samuel , Zhan Tianyu , Drogaris Leonidas , Douglas Kevin , St. John Greg , Espaillat Ramon , Bissonnette Robert 
Published: November 2023

Introduction: We evaluate safety and efficacy of risankizumab (RZB) vs. placebo (PBO) in adult patients with moderate-to-severe non-pustular palmoplantar psoriasis (PPPsO).
Method: IMMprint, a Ph3b study evaluated safety and efficacy of RZB vs. PBO in moderate-to-severe PPPsO patients with a static physician’s global assessment(sPGA) of moderate or severe ≥3, palmoplantar psoriasis area and severity index(PPASI) ≥8 and at least 1 additional PsO plaque. The 52-week treatment was split into period A, patients randomized (1:1) to RZB 150-mg or PBO, and period B, patients continuing RZB or switching from PBO to RZB (PBO/RZB). Primary endpoint was achievement of palmoplantar investigator’s global assessment (ppIGA) 0/1 with at least 2-point reduction from baseline at Wk16. Ranked secondary endpoints include ≥75% & 90% improvement in PPASI (PPASI75, PPASI90), sPGA 0/1 and 100% improvement in PPASI(PPASI100) at Wk16.
Results: Of 174 enrolled, 87(mean age[SD]: 56.9[12.9] years) were randomized to RZB and 87(mean age[SD]: 53.9[14.3] years) were randomized to PBO. Baseline characteristics were similar except for numerical difference in PsA (RZB vs. PBO: 11.5% vs 4.6%, respectively). At Wk16, a significantly higher proportion receiving RZB achieved ppIGA 0/1 than PBO(33.3% vs. 16.1%, p = 0.006). Patients receiving RZB also demonstrated significantly higher responses than patients receiving PBO in all ranked secondary endpoints: PPASI75 (42.5% vs 14.9%, P < 0.001); PPASI90 (27.6% vs 5.7%, p<0.001); sPGA 0/1 (32.2% vs 11.5%, p < 0.001); and PPASI100 (17.2% vs. 1.1%, p < 0.001). Four patients (3 RZB: 1 PBO) discontinued drug in period A. At Wk52, ppIGA 0/1 was achieved by 50.6% of RZB patients and 61.7% of PBO/RZB group. Proportion of patients achieving PPASI75 at Wk52 was 57.5%(RZB) vs. 65.4% (PBO/RZB). Achievement of sPGA 0/1 (%RZB vs. %PBO/RZB) was 43.7% vs. 66.7%; PPASI100 was achieved by 26.4% (RZB) and 37.0% (PBO/RZB) patients at Wk52. Proportion of patients with adverse events were 29.1%(RZB) and 23.0%(PBO) in period A, and 49.4%(RZB) and 35.8% (PBO/RZB) in period B. One RZB patient with prior cardiovascular risk factors had an adjudicated myocardial infarction and subsequently died after 140-day follow-up period. The number of patients with COVID-19 were 3 (RZB; 1 serious infection) and 2(PBO) in period A and 11 (RZB) and 7 (PBO/RZB) in period B.
Conclusion: This study demonstrates RZB can provide effective improvement compared to PBO by Wk16 with continuous improvement until Wk52 with no new safety signals in patients with moderate-to-severe PPPsO.
Maintenance of Clinical Response With Continued Risankizumab Treatment for Moderate-to-Severe Psoriasis Through 304 Weeks: Interim Analysis of the LIMMitless Open-Label Extension Study
Authors: Lebwohl Mark , Bachelez Hervé , Gordon Kenneth , Wu Tianshuang , Chen Michael , Kaplan Blair , Papp Kim 
Published: November 2023

Introduction: Interleukin (IL)-23 is a key regulator of plaque psoriasis pathogenesis. Risankizumab, a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits IL-23 by binding to its p19 subunit, is approved for the treatment of moderate-to-severe plaque psoriasis in adults; however, additional data on long-term maintenance of efficacy with risankizumab treatment are needed. Here we report on the maintenance of clinical response through 304 weeks of continuous risankizumab treatment.
Methods: In this interim analysis, we evaluated patients with moderate-to-severe plaque psoriasis who were randomized to receive risankizumab 150 mg at weeks 0, 4, and 16 and every 12 weeks thereafter during 2 double‑blind, phase 3, 52-week base studies (UltIMMa 1 [NCT02684370] and UltIMMa 2 [NCT02684357]) and enrolled in LIMMitless, an ongoing, phase 3, multicenter, single‑arm, open-label extension (OLE) study (NCT03047395) evaluating the long-term safety and efficacy of continuous risankizumab 150 mg treatment every 12 weeks for plaque psoriasis. Safety was assessed through ≤ 324 weeks by monitoring of treatment‑emergent adverse events through the data cutoff date (May 22, 2023). Efficacy was assessed by the proportion of patients who maintained ≥ 90% or 100% improvement from baseline in Psoriasis Area and Severity Index (PASI 90/100) during LIMMitless and mean improvement in PASI from baseline of the UltIMMa-1/2 study through 252 additional weeks in the LIMMitless study (total of 304 weeks). Missing efficacy data were imputed using modified nonresponder imputation (mNRI), last observation carried forward (LOCF), or observed cases (OC) methodology.
Results: A total of 525 patients were randomized to receive risankizumab 150 mg treatment for 52 weeks in the UltlMMa‑1/2 studies and continued open-label risankizumab 150 mg treatment in the LIMMitless OLE study. Risankizumab was well tolerated through ≤ 324 weeks; no new safety concerns were reported in patients with moderate-to-severe plaque psoriasis. At OLE entry, most patients (451, 85.9%) achieved PASI 90; of those, 422 (93.6%) maintained PASI 90 through week 304 by mNRI (LOCF, 92.7%; OC, 93.8%). Of 320 patients (61.0%) who achieved PASI 100 at OLE entry, 209 (65.3%) maintained PASI 100 through week 304 by mNRI (LOCF, 80.6%; OC, 79.9%). Mean PASI improvement from baseline was generally consistent from OLE entry (95.6% for both LOCF and OC) through week 304 (LOCF, 95.9%; OC, 96.5%).
Conclusion: In this 304-week interim analysis of continuous risankizumab treatment, the safety profile was consistent with previous interim analyses from the LIMMitless study. With continuous risankizumab treatment, most patients maintained PASI 90 or PASI 100 responses from OLE entry through 252 additional weeks in the LIMMitless study.
Analysis of The Effect of Service Quality, Product Quality, and Price on Customer Satisfaction on CV SMART
Authors: Susanto Susanto , Pratama Mohammad Vicky , Pradiptya Adhi 
Published: November 2023

<p><em>This study aims to analyze the effect of service quality,product quality and price on customer satisfaction at Cv smart semarang.</em><em> </em><em>This research was conducted using quantitative methods. The number of research samples was 96 respondents who were consumers of cv smart semarang. The technique used in this study using purposive sampling technique. Quantitative analysis results include validity test,reliability test,classic assumption test (normality test,heteroscedasticity test and multicollinearity test), multiple linear regression test and the last hypothesis test using the T test, F test and the coefficient of determination (R2).</em><em> </em><em>The research results show that service quality, product quality and price have a positive and significant. With the following regression equation Y = 0,222 X1+0,284 X2+0,391 X3. And the magnitude of the coefficient of determination (R2) is 0,609 which means 60,9 percent of consumer satisfaction is influenced by service quality,product quality,and price.</em></p><p><em> </em></p>
Kualitas Mie Basah dengan Substitusi Tepung Bonggol Pisang Kepok (Musa acuminata balbisiana C.) dan Umbi Bit (Beta vulgaris L.)
Authors: Liya Hertanti Beatrik , Pranata Franciscus Sinung , Reni Swasti Yuliana 
Published: November 2023

<em>Noodle is a popular food and mostly consumed by people in Indonesia. The addition of kepok banana corm and beetroot flour as potential local foodstuff is expected to increase nutritional content, especially fibre content in wet noodle product. This research aims to determine the effect of substitution of kepok banana corm and beetroot flour on the physical, chemical, microbiological, and organoleptic qualities of wet noodle, and to determine the best substitution ratio of kepok banana corm and beetroot flour to produce wet noodle with the best quality. This research used a completely randomised design with four treatments are control treatment (100:0:0), A (70:10:20), B (70:15:15), and C (70:20:10) with three repetitions. The results of this research are wet noodles have moisture content of 54,59-62,80%, ash content of 0,79-1,16%, protein content of 3,53-6,60%, insoluble fibre content of 7,81-9,50%, soluble fibre content of 4,84-10,82%, fat content of 2,43-6,48%, carbohydrate content of 25,99-35,56%, and water absorption of 37,38-43,86%. The results of microbiological analysis of wet noodles are ALT 0,43 x 10<sup>2 </sup> to 11,73 x 10<sup>2</sup> (</em><em>) and AKK 0,08 x 10<sup>2 </sup> to 0,26 x 10<sup>2</sup> (</em><em>). The best quality of wet noodle is treatment C based on chemical, physical, microbiological, and organoleptic parameters</em>
Skrining Diabetes Mellitus Melalui Pemeriksaan dan Konsultasi Hasil Gula Darah di Rumah Pelayanan Sosial
Authors: Purnamasari Rina , Rakhmawatie Maya Dian , Diatri Devita , Rohmani Afiana 
Published: November 2023

Latar belakang: Diabetes mellitus (DM) adalah penyakit tidak menular yang ditandai dengan kadar gula darah melebihi normal. Cara mudah untuk mendeteksi apakah terdapat potensi mengalami diabetes yaitu dengan pengecekan kadar gula darah. Tujuan: Kegiatan ini bertujuan untuk melakukan screening DM melalui pemeriksaan kadar glukosa darah dan konsultasi hasil gula darah sewaktu di Rumah Pelayanan Sosial Pucang Gading, Semarang. Metode: Sasaran kegiatan ini adalah lansia yang berjumlah 50 orang. Waktu pelaksanaan yaitu pada Rabu, 31 Mei 2023. Kegiatan meliputi pemeriksaan cek gula darah sewaktu (GDS) dilanjutkan dengan konsultasi hasil gula darah. Hasil: Sebanyak 50 lansia yang ikut berpartisipasi dalam kegiatan ini sebagian besar adalah perempuan (62%), laki – laki (28%). Dari hasil pemeriksan GDS didapatkan rerata kadar GDS 152.12 gr/dl. Lansia yang tidak menderita DM (91%). Kesimpulan: Sebagian besar lansia memiliki kadar GDS yang normal. Namun, tetap perlu dilakukan upaya deteksi dini supaya tidak terjadi komplikasi Diabetes Mellitus.
Kata kunci: diabetes mellitus, gula darah sewaktu, lansia
__________________________________________________________________________________
Background: Diabetes Mellitus (DM) is a non-communicable disease characterized by abnormal blood sugar levels. An easy way to detect whether there is potential for diabetes is to check blood sugar levels. Objective: This activity aims to screen for DM by checking blood glucose levels and consulting blood sugar results. Method: The target of this activity is the 50 elderly in the Rumah Pelayanan Sosial Pucang Gading, Semarang City. This activity was carried out on Wednesday, 31st of May, 2023. After implementation, random blood sugar examination then continued with consultation on blood sugar results. Result: A total of 50 elderly who participated in this activity were mostly women (62%), and men (28%). From the random blood sugar examination results, the average random blood sugar level was 152.12 gr/dl. Elderly who did not suffer from DM (91%). Conclusion: Most of the elderly have normal random blood sugar levels. However, early prevention is still needed to prevent complications of Diabetes Mellitus.
Keywords: diabetes mellitus, elderly, random blood sugar level